Tengjun Biotechnology Corp (TJBH)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tengjun Biotechnology Corp (“Tengjun” or “the Company”) (OTCMKTS: TJBH). Investors who purchased Tengjun securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Tengjun has violated federal securities laws.
On September 5, 2023, Tengjun announced that its previous financial statements on Form 10-K for “the fiscal year ended December 31, 2022, should no longer be relied upon due to accounting methodology errors in such financial statements and that the Board deems it advisable and in the best interests of the Company to restate the financial statements by amending its annual report on Form 10-K for the fiscal year ended December 31, 2022 as soon as reasonably practicable.” On this news, Tengjun’s American Depositary Share (“ADS”) price fell $3.15 per ADS, or 17.64%, to close at $14.71 per ADS on September 5, 2023.
If you are aware of any facts relating to this investigation or purchased Tengjun securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]